PPH — VanEck Pharmaceutical ETF
Healthcare Ranked #172 of 458 tracked ETFs · Issued by VanEck
PPH Price Performance — Growth of $10,000
Value of a $10,000 investment in PPH over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
PPH Drawdown
The "underwater" chart: PPH's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in PPH?
See what a lump sum in PPH would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The VanEck Pharmaceutical ETF (PPH) operates within the Healthcare category, which ETFValuer tracks across 11 distinct funds. Issued by VanEck, this fund holds $879 million in assets under management and trades at a price of $110.63. It currently holds an overall rank of #172 out of 458 tracked ETFs across all categories, receiving an ETFValuer grade of B with a score of 65.1 out of 100. The fund charges an expense ratio of 0.36% and offers a dividend yield of 1.97%. The asset size of $879 million suggests a moderate level of investor adoption relative to the broader universe of 458 tracked funds. These metrics collectively define the fund's standing as a mid-tier option within its specific sector classification.
Over the last trading day, the fund posted a return of +0.62%, followed by a +0.54% gain over the one-week period. Monthly performance accelerated significantly to +5.24%, while the three-month return extended further to +9.84%. Year-to-date gains stand at +8.15%, and the six-month return shows a slight deceleration to +5.41% compared to the three-month trend. The one-year return reached +26.45%, and the three-year return demonstrates substantial long-term growth at +46.19%. This pattern indicates a strong upward trajectory over the longer horizons, with the three-year figure notably exceeding the one-year annualized rate.
The fund carries a Moderate volatility label and a beta of 0.41, indicating lower sensitivity to broad market movements. A Sharpe ratio of 1.18 suggests the fund has generated a favorable amount of excess return per unit of risk taken. However, the maximum drawdown of -18.06% highlights the potential for significant temporary losses during market downturns. The combination of a low beta and moderate volatility implies the fund may experience smaller swings than the broader market, yet the drawdown figure confirms that downside protection is not absolute. Investors should note that while the risk-adjusted returns appear efficient, the fund remains exposed to substantial drawdown events.
AI-generated summary based on the data on this page.
PPH Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | Eli Lilly & Co | 18.70% | $240M |
| 2 | Novartis AG | 10.76% | $138M |
| 3 | Merck & Co Inc | 9.68% | $124M |
| 4 | Pfizer Inc | 5.23% | $67M |
| 5 | Novo Nordisk A/S | 4.81% | $62M |
| 6 | Sanofi SA | 4.73% | $61M |
| 7 | Bristol-Myers Squibb Co | 4.62% | $59M |
| 8 | GSK PLC | 4.58% | $59M |
| 9 | AstraZeneca PLC | 4.40% | $57M |
| 10 | Johnson & Johnson | 4.34% | $56M |
Holdings as of 2026-03-31 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 71.8% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how PPH's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With PPH
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with PPH's top 10 — FVD overlaps most, holding 4 of the same companies as PPH's top 10 (18.3% of PPH's assets).
| ETF | Name | Shared Companies | PPH Weight | Examples |
|---|---|---|---|---|
| FVD | First Trust Value Line Dividend Index Fund | 4 | 18.3% | Sanofi SA, Bristol-Myers Squibb Co, GSK PLC… |
| VHT | Vanguard Health Care Index Fund ETF Shares | 3 | 32.7% | Eli Lilly & Co, Merck & Co Inc, Johnson & Johnson |
| XLV | State Street Health Care Select Sector SPDR ETF | 3 | 32.7% | Eli Lilly & Co, Johnson & Johnson, Merck & Co Inc |
| FHLC | Fidelity MSCI Health Care Index ETF | 3 | 32.7% | Eli Lilly & Co, Merck & Co Inc, Johnson & Johnson |
| FDL | First Trust Morningstar Dividend Leaders Index Fund | 3 | 19.5% | Merck & Co Inc, Pfizer Inc, Bristol-Myers Squibb Co |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.71% (as of 2026-07-23) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 18.70 (as of 2026-07-23) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-06-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What PPH's Fees Cost You
PPH charges an expense ratio of 0.36% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
PPH Dividend Income Estimator
PPH currently yields 1.97%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
PPH Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is 6.39% and average daily volume is 240K/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $879M provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: PPH is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
PPH Performance History
| Period | Return |
|---|---|
| 1-Day | +0.62% |
| 1-Week | +0.54% |
| 1-Month | +5.24% |
| 3-Month | +9.84% |
| 6-Month | +5.41% |
| YTD | +8.15% |
| 1-Year | +26.45% |
| 3-Year | +46.19% |
How PPH Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #66 | B |
XBI | State Street SPDR S&P Biotech ETF | +71.35% | 0.35% | $10.7B |
| #69 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +23.45% | 0.09% | $20.4B |
| #92 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +21.38% | 0.08% | $40.6B |
| #110 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +23.55% | 0.084% | $3.22B |
| #122 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +57.67% | 0.35% | $428M |
| #125 | B |
IBB | iShares Biotechnology ETF | +39.29% | 0.44% | $9.09B |
| #172 | B |
PPH | VanEck Pharmaceutical ETF | +26.45% | 0.36% | $879M |
| #198 | C |
IYH | iShares U.S. Healthcare ETF | +21.01% | 0.38% | $3.16B |
| #293 | C |
IHF | iShares U.S. Healthcare Providers ETF | +30.54% | 0.38% | $1.18B |
| #389 | D |
ARKG | ARK Genomic Revolution ETF | +42.41% | 0.75% | $1.73B |
| #443 | F |
IHI | iShares U.S. Medical Devices ETF | -17.48% | 0.38% | $3.02B |